Browse Technologies
Browse Technologies
Technology Keyword Search
Antibodies/Protein Therapeutics
Search Results
Displaying: 11 - 16 of 16 Results
Lead compounds for the treatment of pain
The invention is a novel synthetic pathway to the generation of nonpeptidic ligands for the mu opioid class of G-protein coupled receptors. The system uses stereochemical variation and acyclic geometric stereocontrol to generate diversity among its…
DBD
- Vivian Berlin
Investigators
- Gregory Verdine
- Bryce Harrison
- Tiffany Gierasch
- Zhangjie Shi
Monoclonal IgE anti-ovalbumin antibody
A laboratory from the Harvard School of Public Health has developed a monoclonal Ig E mouse anti-ovalbumin. This antibody is useful as a positive control in ELISA assays used to measure the level of IgE anti-ovalbumin antibodies in mouse models of…
DBD
- Grant Zimmermann
Investigators
- Lester Kobzik
- Aiyappa Palecanda
Modular conditional knockout: Precise temporal control of protein degradation in living cells
Polyubiquitinated proteins in eukaryotes are directed to the proteasome for degradation. It is generally accepted that proteasome-mediated proteolysis depends strictly upon ubiquitination, as disruption of that process has been observed to halt…
DBD
- Maryanne Fenerjian
Investigators
- George Church
- Daniel Janse
Small-molecule-triggered intein splicing as a universal switch for protein activation
Researchers in the laboratory of Professor David Liu have used directed evolution techniques to evolve an intein-based molecular switch that transduces binding of a small molecule into the activation of an arbitrary protein of interest. To create…
DBD
- Irit Ben-Chelouche
Investigators
- David Liu
- Allen Buskirk
- Sun Peck
Fzd2 - novel anti-cancer therapeutic target
The role of β-catenin accumulation in the development of tumorigenicity has been well documented to date, with various mutations in β-catenin, APC, and axin genes typically to blame. Although β-catenin accumulation plays a role in hepatocellular…
DBD
- Irit Ben-Chelouche
Investigators
- Gavin MacBeath
- Taran Gujral
Continuous Evolution (PACE) of Botulinum Neurotoxins with Reprogrammed Substrate Specificity for Intracellular Protease Therapy
Biomacromolecule-based therapies are of keen interest to the pharmaceutical industry because macromolecules engage in highly specific interactions in biological systems compared to traditional small molecules. Despite their success, macromolecular…
DBD
- Irit Ben-Chelouche
Investigators
- David Liu